Similar to Ramucirumab’s mode of action, Tanibirumab (TTAC-0001) is an anti-VEGFR2 antibody which also binds to the VEGFR2 extracellular domain and blocks binding of VEGF-A, VEGF-C, VEGF-D and VEGF-E, with potent anti-angiogenic activity and tumour growth inhibition in mouse models. Here, KDR is linked to neoplasm.